Nektar Therapeutics
NKTR
Nektar Therapeutics (NKTR) news
Recent news
Nektar Therapeutics - Rezolve-AD study meets all primary and key secondary endpoints for Rezpegaldesleukin 24 mg/kg q2w
Nektar Therapeutics (Nasdaq: NKTR) announced on August 25, 2026, that the REZOLVE-AD Phase 2b study of rezpegaldesleukin met all primary and key secondary endpoints for the 24 µg/kg q2w dosing regimen in patients with moderate-to-severe atopic dermatitis (AD). The study, published in The Lancet ,…
AInvest Wire · 6d agoNektar Therapeutics: JP Morgan resumes coverage with neutral rating; target price $65
AInvest Wire · Aug 21, 2026Nektar 2Q loss/share $1.23
AInvest Wire · Aug 13, 2026Nektar Therapeutics: Canaccord Genuity initiates coverage with buy rating; target price $153
AInvest Wire · Jul 22, 2026Nektar Therapeutics - initial Phase 3 topline data expected mid-2028; BLA submission targeted for 2029
AInvest Wire · Jul 21, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.